Organization
Fulgent Pharma
1 clinical trial
1 abstract
Clinical trial
A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2025-03-31
Abstract
Efficacy from the phase 1 study of FID-007, a novel nanoparticle paclitaxel formulation, in patients with head and neck squamous cell carcinoma.Org: Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business, Fulgent Pharma,